Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome

Blood. 2012 Mar 8;119(10):2239-41. doi: 10.1182/blood-2011-11-393819. Epub 2012 Jan 13.

Abstract

We examined the prevalence and prognostic relevance of bone marrow reticulin fibrosis in 526 patients with World Health Organization-defined polycythemia vera evaluated at the time of initial diagnosis. Seventy-four patients (14%) displayed mostly grade 1 reticulin fibrosis, with only 2 cases showing higher-grade fibrosis. Presenting clinical and laboratory characteristics, including JAK2V617F allele burden, between patients with and without fibrosis were similar for the most part, with the exception of a higher prevalence of palpable splenomegaly in patients with fibrosis (P < .01). Patients with fibrosis were less prone to experience thrombosis during their clinical course (1.1 vs 2.7 per 100 patient-years; P = .03) and more prone to develop post-polycythemia vera myelofibrosis (2.2 vs 0.8 per 100 patient-years; P = .01). There was no significant difference between the 2 groups in terms of overall or leukemia-free survival. The present study clarifies the incidence, degree, and prognostic relevance of bone marrow fibrosis obtained at time of initial diagnosis of polycythemia vera.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow / metabolism
  • Bone Marrow / pathology*
  • Disease Progression
  • Fibrosis
  • Follow-Up Studies
  • Humans
  • Janus Kinase 2 / genetics
  • Leukemia / complications
  • Mutation
  • Polycythemia Vera / complications
  • Polycythemia Vera / genetics
  • Polycythemia Vera / pathology*
  • Primary Myelofibrosis / complications
  • Prognosis
  • Reticulin / metabolism
  • Survival Analysis
  • Thrombosis / complications

Substances

  • Reticulin
  • JAK2 protein, human
  • Janus Kinase 2